# US 2012/0258915 A1 · Proteolysis Resistant Active VEGF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0258915 A1
- Document ID: US20120258915A1
- Status: Published application
- Kind: A1
- Application number: 13/445,016
- Filed: 2012-04-12
- Published: 2012-10-11
- Earliest claimed: 2002-03-08
- Assignees: Bayer Innovation GmbH
- Inventors: Sabine Eming; Thomas Krieg; Stephan Sollberg; Gereon Lauer
- Web page: https://patentgrep.com/patent/US20120258915A1

## CPC

- C07K 14/52: Cytokines; Lymphokines; Interferons
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.

## Claims

### Claim at position 1

-16. (canceled)

### Claim 17

A method for inhibiting plasmin, inducing neoangiogenesis, and/or inhibiting matrix degradation comprising administering to a patient in need thereof an effective amount of a VEGF variant comprising:
an amino acid sequence, wherein said amino acid sequence is the amino acid sequence of a native vascular endothelial growth factor in which at least one amino acid at positions 110 or 111 of the native vascular endothelial growth factor is replaced by proline or is deleted, wherein plasmin is inhibited, neoangiogenesis is induced and/or matrix degradation is inhibited.

### Claim 18 (depends on 17)

The methods of claim 17, wherein at least one further amino acid at the other of the positions 110 or 111 of the VEGF variant is replaced or is deleted.

### Claim 19 (depends on 17)

The methods of claim 17, wherein an alanine at position 111 of the native vascular endothelial growth factor is replaced by proline.

### Claim 20 (depends on 19)

The methods of claim 19, wherein an arginine at position 110 of the native vascular endothelial growth factor is replaced by another amino acid.

### Claim 21 (depends on 20)

The methods of claim 20, wherein said another amino acid is proline.

### Claim 22 (depends on 17)

The methods of claim 17, wherein an arginine at position 110 of the native vascular endothelial growth factor is replaced by proline.

### Claim 23 (depends on 17)

The methods of claim 17, wherein an alanine at position 111 of the native vascular endothelial growth factor is replaced by another amino acid.

### Claim 24 (depends on 23)

The method of claim 23, wherein said another amino acid is proline.

### Claim 25 (depends on 17)

The methods of claim 17, wherein the VEGF variant is in the form of any of the splice variants VEGF121, VEGF145, VEGF165, VEGF183, VEGF189 or VEGF206.

### Claim 26 (depends on 17)

The methods of claim 17, wherein the VEGF165 variant has one of the amino acid sequences SEQ ID NO:1 or SEQ ID NO:2.

### Claim 27 (depends on 17)

The methods of claim 17, wherein the amino acid chain is modified or derivatized and/or comprises mutations, insertions and/or deletions and/or has a signal sequence.

### Claim 28 (depends on 27)

The method of claim 27, wherein the signal sequence is connected N-terminally to the amino acid chain of the VEGF variant and has the sequence of SEQ ID NO:3.

### Claim 29 (depends on 17)

The method of claim 17, wherein the an amino acid at position 111 of the native vascular endothelial growth factor is replaced by proline or is deleted and wherein an amino acid at position 110 is maintained or replaced with lysine.

### Claim 30 (depends on 29)

The method of claim 29, wherein the amino acid at position 111 of the native vascular endothelial growth factor is replaced by proline.

### Claim 31 (depends on 30)

The method of claim 30, wherein the amino acid at position 110 of the native vascular endothelial growth factor is replaced by lysine.
